Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year Low – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $2.98 and last traded at $2.9950, with a volume of 7938989 shares traded. The stock had previously closed at $3.15.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Bank of America reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Finally, Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

The business’s 50-day moving average price is $3.74 and its 200 day moving average price is $4.48. The stock has a market capitalization of $1.55 billion, a PE ratio of -1.99 and a beta of 0.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.07. The company had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm’s revenue was up 671.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.53) earnings per share. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $3.35, for a total value of $94,798.30. Following the sale, the chief executive officer owned 2,262,085 shares of the company’s stock, valued at $7,577,984.75. This trade represents a 1.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Ben R. Taylor sold 21,383 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $4.18, for a total value of $89,380.94. Following the sale, the chief financial officer owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. This trade represents a 2.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 511,063 shares of company stock worth $2,135,702 in the last ninety days. 8.43% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Xponance Inc. increased its holdings in shares of Recursion Pharmaceuticals by 8.0% in the 3rd quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after buying an additional 2,221 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after acquiring an additional 2,428 shares during the last quarter. Equitable Holdings Inc. grew its position in Recursion Pharmaceuticals by 7.1% in the third quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock worth $192,000 after acquiring an additional 2,600 shares in the last quarter. Cherry Creek Investment Advisors Inc. grew its position in Recursion Pharmaceuticals by 4.1% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company’s stock worth $326,000 after acquiring an additional 2,649 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Recursion Pharmaceuticals by 1.2% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock valued at $954,000 after acquiring an additional 2,753 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.